Company News for November 17, 2010 - Corporate Summary

• Target’s (NYSE:TGT) third quarter matched sales and earnings estimates, with earnings of $0.68 and revenues $15.61 billion

• BJ’s Wholesale Club (NYSE:BJ) posed third quarter results beating estimates by $0.07 at $0.43, on revenues up 4.9% YoY to $2.6 billion, in-line with expectations

• Human Genome Sciences (NASDAQ:HGSI) resumed trading this morning after news that its lupus-fighting drug, Benlysta, developed with GlaxoSmithKline (NYSE:GSK), was recommended for FDA approval by an FDA advisory panel. Even so, two firms downgraded Human Genome shares

• Potash (NYSE:POT), recently successful in fighting off BHP Billiton’s (NYSE:BHP) takeover bid, initiated a $2 billion, one-year share buyback program

• Goldman Sachs (NYSE:GS) downgraded Norfolk Southern (NYSE:NSC) from “neutral” to “sell,” taking its price target from $62 to $59

• FBR maintained its “outperform” rating on Marvell (NASDAQ:MRVL), with a price target of $25

• Jefferies (NYSE:JEF) maintained a “buy” on Home Depot (NYSE:HD), with a price target of $36

• Goldman Sachs (NYSE:GS) upgraded CSX (NYSE:CSX) from “sell” to “neutral,” lifting its price target from $60 to $63

Company News for November 17, 2010 – Corporate Summary

SIGN UP TO NEWSLETTER

Free E-Book

Recent Posts